News & Blogs

Commitment to Seniors Opposes Draft Regulations Under the Comprehensive Outbound Investment National Security (COINS) Act

Washington, D.C. – October 22, 2026 – Commitment to Seniors (C2S), a project of American Commitment, opposes the U.S. Treasury Department’s draft regulations under the Comprehensive Outbound Investment National Security (COINS) Act, which would expand restrictions on outbound investment in biopharmaceuticals.

American seniors have the most to lose when government policies stand in the way of medical progress. Treasury’s proposed expansion of investment restrictions threatens to do exactly that. By preventing American companies from pursuing and developing promising new medicines, these restrictions put future treatments further out of reach for older Americans who depend on continued medical breakthroughs.

Developing these treatments and therapies requires years of research, significant private investment, and access to promising scientific discoveries around the world. Restricting access to Chinese biotechnology risks leaving emerging treatments in the hands of Chinese developers while American companies lose opportunities to advance them for patients here at home. Meanwhile, other international competitors could continue pursuing those same discoveries, potentially leaving American seniors waiting longer for the lifesaving medicines they need.

The U.S. is the global leader in pharmaceutical innovation, but China is closing in fast, and they will start to dominate if we advance policies that restrict research and development instead of those that strengthen America’s innovation ecosystem.

While national security is an essential responsibility of the federal government, protecting it should not come at the expense of patients living with chronic illnesses, including cancer and Alzheimer’s diseases, who depend on continued medical innovation. Treasury should specifically address transactions that pose genuine national security threats without restricting partnerships that can bring new therapies to the U.S. market. American seniors deserve access to the best treatments modern medicine can offer, regardless of where the underlying science originated. Instead of creating additional barriers to medical progress, policies should pave the way for medical breakthroughs that improve and extend seniors’ lives.